Fact CheckerSign in

NCT06555965Recruiting

STXBP1 and SYNGAP1 Related Disorders Natural History Study

STXBP1 and SYNGAP1 Related Disorders (RD) Natural History Study

Source: ClinicalTrials.gov · Last updated 29 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The purpose of this study is to find out more about STXBP1 and SYNGAP1 related disorders. The information gathered by this study will be used to prepare for clinical treatment trials. The primary objective of the study is to better define and outline the clinical spectrum of STXBP1 and SYNGAP1 through detailed developmental, seizure, and quality of life assessments as an extension of routine clinical care.

Status (registry)
Recruiting
Study type
Observational
Enrollment
600 (estimated)
First submitted
13 Aug 2024
Start date
30 Aug 2023
Primary completion date
30 Aug 2028
Lead sponsor
Children's Hospital of Philadelphia
Diseases
Epilepsy
NCT number
NCT06555965

What you commit to

  • Study type: Observational
  • Planned participants: 600
  • From 30 Aug 2023 to the primary completion date, 30 Aug 2028
  • 5 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • The presence of a significant non-STXBP1-RD or non-SYNGAP1-RD related central nervous impairment/behavioral disturbance that would confound the scientific rigor or interpretation of results of the study.
  • History of intraventricular hemorrhage, structural brain deficit or congenital heart disease

Age

  • Pregnant women or females of age of menarche who are found to be pregnant upon urine pregnancy testing.

Other

  • The presence of a confirmed mutation in a gene other than STXBP1 or SYNGAP1 that is known to contribute to a neurodevelopmental disability. This includes full gene deletions of STXBP1 or SYNGAP1 that include other genes beyond STXBP1 or SYNGAP1.
  • The presence of a clinical comorbidity deemed by the investigator to potentially confound the typical presentation of STXBP1-RD or SYNGAP1-RD.

Who the study is looking for

  • Male or female of any age.
  • Presence of a STXBP1 or SYNGAP1 gene mutation. The variant in STXBP1 or SYNGAP1 must be classified as causative based on clinical and variant classification criteria. Historical documentation is sufficient to support eligibility for the study. Confirmatory testing will be obtained, if necessary, at baseline and performed by a CLIA certified laboratory.

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (5)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Children's Hospital Colorado
Coordinator of this site? Confirm its status
AuroraUnited StatesRecruiting
Texas Children's Hospital
Coordinator of this site? Confirm its status
HoustonUnited StatesRecruiting
Weill Cornell Medicine
Coordinator of this site? Confirm its status
New YorkUnited StatesRecruiting
Stanford Medicine Children's Health
Coordinator of this site? Confirm its status
Palo AltoUnited StatesRecruiting
The Children's Hospital Of Philadelphia
Coordinator of this site? Confirm its status
PhiladelphiaUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.